Source comparison
BPC-157 Wound Healing Research: Study Comparison
Excisional skin wounds (rats) Wound closure at day 7 60% closure vs 35% (71% faster) VEGFR2 upregulation, fibroblast migration Rodent skin heals via contraction; human relevance uncertain Thermal burn injury (rats) Re-epithelialization at day 10 40% faster vs
This comparison does not assign a generated winner or score.
- Excisional skin wounds (rats)
- Wound closure at day 7
- 60% closure vs 35% (71% faster)
- VEGFR2 upregulation, fibroblast migration
- Rodent skin heals via contraction; human relevance uncertain
- Thermal burn injury (rats)
- Re-epithelialization at day 10
- 40% faster vs control
- Reduced TNF-α/IL-6, preserved microvascular flow
- No dose-response data; single timepoint measurement
- Achilles tendon transection
- Tensile strength at day 14
- 50% higher load-to-failure
- Increased Type I collagen density, FAK-paxillin activation
- Surgical model; doesn't reflect chronic tendinopathy
- Gastric ulcer (ethanol-induced)
- Ulcer area at day 7
- 45–55% reduction vs saline
- Mucosal blood flow preservation, oxidative stress reduction
- Acute injury model; limited relevance to chronic ulcers
- The pattern across these studies is clear: BPC-157 consistently accelerates healing across injury types when measured objectively. What remains unclear is whether these rodent-model effects translate proportionally to human tissue, what dosing and timing protocols optimize outcomes, and how the peptide compares to existing clinical interventions.